Regulation, Patents, and Diagnostics

Charles Duan American University Washington College of Law Sean Tu West Virginia University College of Law

ASLME 48th Health Law Professors Conference Boston University School of Law June 6, 2025

Two Lawsuits



(I assume that this particularly awful graphic of a six-eyed chief justice was AI-generated.)

Discoveries in Health Policy, https://www.discoveriesinhealthpolicy.com/2025/02/acla-vs-fda-on-ldt-hearing-in-texas.html.

In This Talk

- Two stories
- ► A theory
- Balancing
- ► A win-win?

Molecular Diagnostics



Ricardipus, https://commons.wikimedia.org/wiki/File:Affymetrix_5.0_microarray.jpg.

Two Regimes

Laboratory-developed	
tests (LDTs)	Commercial tests
CMS (CLIA)	FDA (medical devices)
Per laboratory	Per test
Proficiency and	Safety and
accreditation	effectiveness
Low cost	High cost

AMP v. Myriad




SHYCITYNikon, End Patents of Life Forms, https://www.flickr.com/photos/kgnixer/7227341916/.

Barriers to Entry



PantheraLeo1359531, https://commons.wikimedia.org/wiki/File:Hinweis_Abstrichstelle_Hof_20200407_08.jpg.

Equilibria



Pros and Cons

Benefits of LDT regulation:

- Individual test validation
- Patient confidence
- Lower health care costs

Benefits of low-patent market:

- Competition
- Rapid innovation
- Information sharing

A Possible Approach



Sam Donvil, https://commons.wikimedia.org/wiki/File:20170620_sharing_is_caring_032_s.jpg.